← All Chromadex CORP filings

Chromadex CORP Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

CDXC
Chromadex CORP
SCHEDULE: Vanguard Group Amends Niagen Bioscience Stake
The Vanguard Group updated its beneficial ownership in Niagen Bioscience Inc., reporting a 4.11% stake as of December 31, 2025.
CDXC
Chromadex CORP
SCHEDULE: Vanguard Discloses 5.04% Stake in Niagen Bioscience
The Vanguard Group has filed a Schedule 13G, reporting a 5.04% beneficial ownership stake in Niagen Bioscience Inc.